Table 2.
CMML/aCML; JAK2V617F positive cohort
| Patient | Sex | Age, y | WBC count, × 109/L | Plt count, × 109/L | Hb, g/L | Karyotype | Splenomegaly | Diagnosis | Progression to AML | Ras mutation | Treatment | Survival, mo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 65 | 53.9 | 46 | 133 | Diploid | Yes | CMML | Yes | No | Hydrea, 9NC, oral topotecan | 62 |
| 2 | M | 55 | 30.4 | 51 | 134 | Diploid | Yes | CMML | No | NRAS codon 12 | Topotecan/Ara-C, Allo-SCT | 75+ |
| 3 | M | 70 | 48.0 | 15 | 63 | Diploid | Yes | CMML | No | KRAS codon 13 | Daunorubicin, Ara-C, thalidomide | 0.2 |
| 4 | M | 54 | 37.1 | 22 | 108 | Diploid | Yes | CMML | No | No | FTI | 57 |
| 5 | F | 71 | 24.9 | 272 | 155 | Diploid | No | CMML | No | No | Hydrea | 36+ |
| 6 | M | 74 | 4.6 | 177 | 127 | Diploid | No | CMML | No | No | eloposide, skin XRT | 27+ |
| 7 | M | 47 | NA | NA | NA | Diploid, trisomy 8 at transformation to AML | Yes | aCML | Yes | No | Hydrea, IFN, Allo-SCT | 60+ |
| 8 | M | 79 | 6.9 | 99 | 135 | Diploid | Yes | CMML | Yes | No | None | 33+ |
WBC indicates white blood cell; Plt, platelet; Hb, hemoglobin; 9NC, 9-nitrocamptothecin; Ara-C, arabinosyl cytosine; Allo-SCT, allogeneic stem cell transplantation; FTI, farnesyl transferase inhibitors; XRT, radiotherapy; NA, not available; and IFN, interferon.